<DOC>
	<DOCNO>NCT01779531</DOCNO>
	<brief_summary>Human epidermalgrowth factor receptor-2 ( HER2 ) negative Luminal B subtype breast cancer patient include . After 4 cycle Capecitabine combine Docetaxel ( XT ) protocol neoadjuvant chemotherapy , reach partial response ( PR ) pathological complete response ( pCR ) randomly divide group treat XT protocol group Capecitabine combine Epirubicin Cyclophosphamide ( XEC ) protocol , compare disease free survival ( DFS ) overall survival ( OS ) two subgroup .</brief_summary>
	<brief_title>Compare Outcomes XT XEC Adjuvant Chemotherapy HER2-negative Luminal B Breast Cancer Patients</brief_title>
	<detailed_description>Individualized treatment breast cancer become one main direction clinical research area breast cancer , individualize treatment estrogen receptor ( ER ) positive patient cover 65 % total case vital importance . Historical research show among ER-positive HER2-negative breast cancer , Luminal B breast cancer Ki67 &gt; 14 % likely benefit chemotherapy , compare Luminal A breast cancer Ki67 &lt; 14 % . And result previous research show , neoadjuvant XT protocol 17 % pCR rate Luminal B subtype breast cancer.However , n't reach pCR , 've get evidence whether switch Anthracycline-based post operative protocol benefit them.So , sketch randomize controlled multicentric phase III clinical trail.HER2 negative Luminal B subtype breast cancer patient include . After 4 cycle XT protocol neoadjuvant chemotherapy , reach PR pCR randomly divide group treat XT protocol group XEC protocol , compare DFS OS two subgroup .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<criteria>Chinese population surgery patient invasive breast cancer； Stage IIIII； ER positive； HER2 negative； Ki67≥14 % ； Aged 18 70 year old； The maximum diameter primary tumor great 1cm； ECOG score 01 points； Have adequate baseline bone marrow organ function reserve : absolute neutrophil count ≥ 1500/mm3 , platelet count ≥ 8g/dl ; ≥ 100000/mm3 hemoglobin concentration serum creatinine ≤ 1.5 time upper limit normal ; aspartate aminotransferase alanine aminotransferase ≤ 2.5 time upper limit normal , bilirubin ≤ 1.5 time upper limit normal ; leave ventricular ejection fraction ( LVEF ) ≥ 50 % Non Chinese population patients； Non invasive cancer patient ; Inflammatory Breast Cancer patient ; Metastatic breast cancer patient ; HER2 positive patient ; Ki67 &lt; 14 % patient ; No adequateBaseline bone marrow organ function reserve ; ECOG PS score ≥ 2 point ; Younger 18 year age great 70 year old ; Already accept therapy include chemotherapy , endocrine therapy target therapy neoadjuvant treatment ; HER2positive patient leave ventricular ejection fraction le 55 % receive Herceptin ; Known allergy docetaxel , capecitabine , epirubicin , ring phosphonamide .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>HER2-negative Luminal B breast cancer</keyword>
</DOC>